Advances in dendrimer-mediated targeted drug delivery to the brain

Treating diseases of the central nervous system (CNS) still remains a problem for the researchers. Existence of specific anatomical barriers, especially the blood brain barrier (BBB), restricts the brain mobility and hinders the effectiveness of different drug therapies. Rapid nanotechnological developments have given promising solutions to this challenge. Therefore, during the last few decades, a variety of nanocarriers have been designed to deliver drugs to the brain. Dendrimers are highly branched, three-dimensional macromolecules with tailor-made surface functionality and internal cavities that make them interesting carrier to deliver the drug to the brain. Significant advances have been made in dendrimer-mediated targeted delivery to the brain in last two decades. This review article deals majorly with recent advances in dendrimer-mediated delivery to the brain with discussions on the mechanisms of biodistribution and toxicity of dendrimer crossing the BBB. This will assist researchers in designing the new strategies to deal with major challenges related to the targeted delivery of CNS therapeutic agents to the brain.

Automated summary

Treatment of central nervous system (CNS) diseases remains a challenge due to the presence of the blood brain barrier (BBB) restricting drug delivery. Recent advancements in nanotechnology have led to the design of various nanocarriers for drug delivery to the brain. Dendrimers, with their tailored surface functionality and internal cavities, have shown significant progress in delivering drugs to the brain over the past two decades.